Leerink Partnrs Reaffirms Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC)
The Cerbat Gem - 2024-04-27T01:24:42.000Z

Leerink Partnrs reiterated their outperform rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a research report sent to investors on Tuesday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Cartesian Therapeutics’ Q1 2024 earnings at ($1.34) EPS, Q2 2024 earnings at ($1.38) EPS, Q3 2024 earnings at ($1.27) EPS, Q4 2024 […] Read this story